Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
From 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making …
Read moreOur previous article explored how TrumpRx might influence drug pricing in the US, the potential …
Read moreThis on-demand session provides a concise update on recent developments in Most Favoured Nation (MFN…
Read moreWorld Evidence, Pricing and Access (World EPA) Congress 2026 brought together market access leaders,…
Read moreObesity medicines (OMs), including GLP-1 receptor agonists such as semaglutide (Wegovy®) and tirzep…
Read moreManufacturers looking to optimise access for their orphan drugs need to navigate a complex environme…
Read moreTrumpRx, the most recent direct-to-consumer platform aimed at cutting drug prices for Amer…
Read moreThe price of innovative, next generation therapies has outpaced payer budgets for som…
Read moreIn 2026, U.S. policy shifts will link domestic US prices to internatio…
Read more